Ursodeoxycholic acid relieves clinical severity of COVID-19 in patients with chronic liver diseases
The study suggests that UDCA therapy may improve clinical outcomes in patients with chronic liver diseases patients who are infected with SARS-CoV-2, highlighting its potential role in improving prognosis within this vulnerable population. However, further research is required to validate these findings and to elucidate the mechanisms underlying UDCA's protective effect.
Authors
- Changrong Yuan (ORCID: https://orcid.org/0000-0001-8480-2569)
- Jinyu Wang (ORCID: https://orcid.org/0000-0001-5593-9582)
- Jiming Zhang (ORCID: https://orcid.org/0000-0001-5820-950X)
- Jie Tong (ORCID: https://orcid.org/0000-0002-8753-0340)
- Yunhui Yang (ORCID: https://orcid.org/0000-0002-2550-3822)
- Tiantian Hu
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fmed.2025.1494248
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Natural Science Foundation of China
- Shanghai Shen Kang Hospital Development Center